

Update from the Pharmaceutical Benefits Advisory Committee (PBAC) August 2026

On 30 July 2026, the PBAC held an Out of Session meeting to address the upcoming delisting of the goserelin 3.6 mg implant (Zoladex Implant™) from the Pharmaceutical Benefits Scheme (PBS), scheduled for November 2026.

With more than 51,000 Australian women currently using goserelin, its removal presents a significant clinical impact. Prescribing data shows that less than 1% of goserelin prescriptions are private, confirming that patients rely heavily on public subsidies for GnRH agonist therapies across key indications—including hormone receptor-positive breast cancer, endometriosis, and prevention of chemotherapy-induced premature ovarian failure.

To ensure continuity of care, the PBAC considered a request to broaden the PBS listing of triptorelin to an unrestricted category. The Committee confirmed that the revised eligibility criteria for triptorelin will support prescribers across all current patient populations, enabling clinicians to transition patients smoothly from goserelin based on evidence-based practice and clinical guidelines.

Outcomes from this PBAC meeting were published on the PBS website on 17 August 2026.

The PBAC continues to welcome the clinician and patient input it receives, and the ongoing relationships with organisations and groups as it increasingly works to deliver outcomes beyond the sequence of PBAC meeting items to broader considerations across clinical management and access priorities.

The PBAC consideration of clinician and patient input is not limited to only the consultation hub submissions on the meeting agenda items, as often the Committee determines the need to consult with clinicians and patients who may not be able to engage with the Committee in this format initially, or at other points in time.

We also consider that the various forms of engagement occurring in a more regular and comprehensive manner serve the stakeholder and PBAC processes beyond merely the number of items on an agenda, or the volume of written inputs related to specific products alone.

PBAC will continue to engage with all stakeholders to ensure the best outcomes possible can be realised for all patients and their clinicians.

PBAC thanks all the many groups and individuals for their time and efforts to support these engagements and the PBS functions overall.

The next PBAC meeting will be the 1-day **Intracycle meeting being held 4 September 2026.**

Professor Robyn Ward AM

Chair, PBAC

Ms Jo Watson

Deputy Chair, PBAC